Harnessing the Suprachoroidal Space for the Treatment of Pos -

Name: Harnessing the Suprachoroidal Space for the Treatment of Posterior Segment Eye Diseases
Uploaded: 2022-01-05T05:00:00+00:00
Duration: 1 h 15 min 30 s
Description: This symposium focuses on the suprachoroidal space as a novel route of drug delivery for the treatment of retinal diseases such as uveitic macular edema, d

Media formats available:

Details

Presenters

Overview
This symposium focuses on the suprachoroidal space as a novel route of drug delivery for the treatment of retinal diseases such as uveitic macular edema, diabetic retinopathy/diabetic macular edema, and neovascular age-related macular degeneration.
Join the faculty for an insightful presentation on key trials examining the suprachoroidal space injections and proper administration techniques, followed by an engaging discussion on how these advanced therapies may alter the treatment landscape.
This activity is supported by an unrestricted educational grant from Bausch + Lomb.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Interpret results of key trials examining the suprachoroidal space injections for the treatment of retinal diseases and how new data may eventually influence practice.
- Describe proper administration techniques of suprachoroidal injections, solutions to common challenges, and best practices in patient education and informed consent.
- Differentiate future applications of suprachoroidal injections and how advanced therapies may alter the treatment landscape.
Accreditation
Accreditation & Designation Statements
Provided by Evolve Medical Education

Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, earns credit toward the Lifelong Learning requirement[s] for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting credit.
Participation Method
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Faculty and Disclosures
Dilraj Grewal, MD
Associate Professor of Ophthalmology
Duke Eye Center
Duke University School of Medicine
Durham, NC

Sunil K. Srivastava, MD
Surgical Retina Fellowship Director
Cleveland Clinic
Cole Eye Institute
Cleveland, OH

Steven Yeh, MD
Truhlsen Eye Institute
University of Nebraska Medical Center
Emory University School of Medicine
Adjunct Professor
Omaha, NE

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Dilraj Grewal, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, EyePoint Pharmaceuticals, Genentech, IvericBio, and Novartis.
Sunil K. Srivastava, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: AbbVie, Allergan, Bausch + Lomb, Carl Zeiss Meditec, Clearside Biosciences, Eyevensys, Gilead, Jcyte, Optos, Regeneron, Sanofi, Santen, and Novartis. Grant/Research Support: Allergan, Bausch + Lomb, Clearside Biosciences, Carl Zeiss, Meditec, EyePoint Pharmaceuticals, Eyevensys, Jcyte, Novartis, Sanofi, and Santen.
Steven Yeh, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Adverum, Bausch + Lomb, Clearside Biosciences, and Regenxbio.
The Evolve staff, planners, and reviewers have no financial relationships with commercial interests.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Bausch + Lomb.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 01/05/2022
Expiration Date: 01/05/2023

Sunil K. Srivastava, MD

Guest

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Overcoming Cultural and Communication Disconnects, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
Overcoming Cultural and Communication Disconnects, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
CME/CE
Overcoming Cultural and Communication Disconnects, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
David Chin Yee, MD, FASRS
0.25 credits
- David Chin Yee, MD, FASRS
0.25 credits
Patient at High Risk of Loss to Follow-Up, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
Patient at High Risk of Loss to Follow-Up, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
CME/CE
Patient at High Risk of Loss to Follow-Up, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
Deepak Sambhara, MD
0.25 credits
- Deepak Sambhara, MD
0.25 credits
Phaco Reloaded: Level Up Your Cataract Game
Phaco Reloaded: Level Up Your Cataract Game
CME/CE
Phaco Reloaded: Level Up Your Cataract Game
Eric D. Donnenfeld, MD; Marjan Farid, MD
1.00 credit
- Eric D. Donnenfeld, MD
- Marjan Farid, MD
- Jason J. Jones, MD
- Eva I. Liang, MD, FACS
- Carlton Yuen, MD
1.00 credit
MinuteCE®
Lighting the Way: Exploring the Potential of Photobiomodulation for Dry AMD Treatment
Janis T. Eells, Ph.D.; David Boyer, MD
1.00 credit 8 episodes
- Janis T. Eells, Ph.D.
- David Boyer, MD
- Diana V. Do, MD
- Marion Munk, MD, Ph.D
1.00 credit 8 episodes

Harnessing the Suprachoroidal Space for the Treatment of Posterior Segment Eye Diseases

Recommended

Title